Article | Published:

Nanofluidic device for continuous multiparameter quality assurance of biologics

Nature Nanotechnology volume 12, pages 804812 (2017) | Download Citation

Abstract

Process analytical technology (PAT) is critical for the manufacture of high-quality biologics as it enables continuous, real-time and on-line/at-line monitoring during biomanufacturing processes. The conventional analytical tools currently used have many restrictions to realizing the PAT of current and future biomanufacturing. Here we describe a nanofluidic device for the continuous monitoring of biologics’ purity and bioactivity with high sensitivity, resolution and speed. Periodic and angled nanofilter arrays served as the molecular sieve structures to conduct a continuous size-based analysis of biologics. A multiparameter quality monitoring of three separate commercial biologic samples within 50 minutes has been demonstrated, with 20 µl of sample consumption, inclusive of dead volume in the reservoirs. Additionally, a proof-of-concept prototype system, which integrates an on-line sample-preparation system and the nanofluidic device, was demonstrated for at-line monitoring. Thus, the system is ideal for on-site monitoring, and the real-time quality assurance of biologics throughout the biomanufacturing processes.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    (Re)defining biopharmaceutical. Nat. Biotechnol. 26, 743–751 (2008).

  2. 2.

    Early development of therapeutic biologics-pharmacokinetics. Curr. Drug Metab. 7, 15–21 (2006).

  3. 3.

    , & Protein therapeutics—a summary and pharmacological classification. Nat. Rev. Drug Discov. 7, 21–39 (2008).

  4. 4.

    & Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat. Rev. Rheumatol. 5, 578–582 (2009).

  5. 5.

    , , & Biologic and therapeutic role of HER2 in cancer. Oncogene 22, 6570–6578 (2003).

  6. 6.

    et al. Expression in Escherichia coli of chemically synthesized genes for human insulin. Proc. Natl Acad. Sci. USA 76, 106–110 (1979).

  7. 7.

    & Guide to Biotechnology 2008 (Biotechnology Industry Organization, 2008).

  8. 8.

    , World Biological Drugs Market 2013–2023 (Visiongain, 2013).

  9. 9.

    , World Preview 2015, Outlook to 2020 (EvaluatePharma, 2015).

  10. 10.

    Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int. J. Pharm. 185, 129–188 (1999).

  11. 11.

    & Protein drug stability: a formulation challenge. Nat. Rev. Drug Discov. 4, 298–306 (2005).

  12. 12.

    et al. Safety-related regulatory actions for biologicals approved in the United States and the European Union. J. Am. Med. Assoc. 300, 1887–1896 (2008).

  13. 13.

    , , & Advances in on-line monitoring and control of mammalian cell cultures: supporting the PAT initiative. Biotechnol. Adv. 27, 726–732 (2009).

  14. 14.

    , & Process analytical technology (PAT) for biopharmaceutical products. Anal. Bioanal. Chem. 398, 137–154 (2010).

  15. 15.

    , , & Towards real-time monitoring of therapeutic protein quality in mammalian cell processes. Curr. Opin. Biotechnol. 30, 161–167 (2014).

  16. 16.

    , , , & On-line sequential injection-capillary electrophoresis for near-real-time monitoring of extracellular lactate in cell culture flasks. J. Chromatogr. A 1323, 157–162 (2014).

  17. 17.

    , & Development of at-line assay to monitor charge variants of MAbs during production. Biotechnol. Prog. 30, 249–255 (2014).

  18. 18.

    , , , & Integrated preconcentration SDS–PAGE of proteins in microchips using photopatterned cross-linked polyacrylamide gels. Anal. Chem. 78, 4976–4984 (2006).

  19. 19.

    , & A nanofilter array chip for fast gel-free biomolecule separation. Appl. Phys. Lett. 87, 263902 (2005).

  20. 20.

    & Separation of long DNA molecules in a microfabricated entropic trap array. Science 288, 1026–1029 (2000).

  21. 21.

    et al. Protein sizing on a microchip. Anal. Chem. 73, 1207–1212 (2001).

  22. 22.

    et al. A DNA prism for high-speed continuous fractionation of large DNA molecules. Nat. Biotechnol. 20, 1048–1051 (2002).

  23. 23.

    , , , & A patterned anisotropic nanofluidic sieving structure for continuous-flow separation of DNA and proteins. Nat. Nanotech. 2, 121–128 (2007).

  24. 24.

    , , & Rapid quantification of disease-marker proteins using continuous-flow immunoseparation in a nanosieve fluidic device. Anal. Chem. 81, 7067–7074 (2009).

  25. 25.

    , & Continuous-flow biomolecule concentration and detection in a slanted nanofilter array. Lab Chip 12, 4441–4448 (2012).

  26. 26.

    & Characterization and optimization of an entropic trap for DNA separation. Anal. Chem. 74, 394–401 (2002).

  27. 27.

    , & Decreasing effective nanofluidic filter size by modulating electrical double layers: separation enhancement in microfabricated nanofluidic filters. Electrophoresis 29, 4646–4651 (2008).

  28. 28.

    , & Molecular sieving in periodic free-energy landscapes created by patterned nanofilter arrays. Phys. Rev. Lett. 97, 018103 (2006).

  29. 29.

    , & A reversed-phase high-performance liquid chromatographic method for characterization of biosynthetic human growth hormone. Anal. Biochem. 167, 199–209 (1987).

  30. 30.

    , , , & High-performance size-exclusion chromatographic determination of the potency of biosynthetic human growth hormone products. J. Chromatogr. A 435, 307–318 (1988).

  31. 31.

    , , & Process for preparing and purifying alpha-interferon. US patent 5196323 A (1993).

  32. 32.

    & Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor (GM-CSF). US patent 5162111 A (1992).

  33. 33.

    The Challenge of CMC Regulatory Compliance for Biopharmaceuticals and Other Biologics (Springer, 2013).

  34. 34.

    , , & Protein aggregation: pathways, induction factors and analysis. J. Pharm. Sci. 98, 2909–2934 (2009).

  35. 35.

    Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm. 289, 1–30 (2005).

  36. 36.

    et al. Forced degradation of therapeutic proteins. J. Pharm. Sci. 101, 895–913 (2012).

  37. 37.

    International Council of Harmonisation. Guideline for the photostability testing of new drug substances and products. Fed. Regis. 62, 27115–27122 (1997).

  38. 38.

    et al. Control systems technology in the advanced manufacturing of biologic drug. In 2015 IEEE Conf. Control Applications 1505–1515 (2015).

  39. 39.

    et al. On-demand continuous-flow production of pharmaceuticals in a compact, reconfigurable system. Science 352, 61–67 (2016).

  40. 40.

    , & Continuous-flow bioseparation using microfabricated anisotropic nanofluidic sieving structures. Nat. Protoc. 4, 1681–1698 (2009).

  41. 41.

    & Fabrication and characterization of 20 nm planar nanofluidic channels by glass–glass and glass–silicon bonding. Lab Chip 5, 837–844 (2005).

  42. 42.

    , , , & Design of peptide affinity ligands for S-protein: a comparison of combinatorial and de novo design strategies. Mol. Divers. 17, 357–369 (2013).

  43. 43.

    et al. Single-molecule studies of repressor–DNA interactions show long-range interactions. Proc. Natl Acad. Sci. USA 102, 9796–9801 (2005).

  44. 44.

    et al. A facile microdialysis interface for on-line desalting and identification of proteins by nano-electrospray ionization mass spectrometry. Rapid Commun. Mass Spectrom. 22, 2391–2397 (2008).

Download references

Acknowledgements

We thank P. Mao for providing advice on the nanofilter fabrication, the MIT Microsystems Technology Laboratories for support in the fabrication, P. W. Barone for discussion and assistance with the sample handling and J.-F. P. Hamel for his support in the cell culture and analysis. This work was mainly supported by the Defense Advanced Research Projects Agency and SPAWAR Systems Center Pacific (N66001-13-C-4025) to S.H.K., D.C., W.O., T.K., P.K. and J.H. a Siebel fellowship to W.O. and a Samsung Scholarship to T.K.

Author information

Affiliations

  1. Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA

    • Sung Hee Ko
    • , Wei Ouyang
    • , Taehong Kwon
    •  & Jongyoon Han
  2. Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York 12180, USA

    • Divya Chandra
    •  & Pankaj Karande
  3. Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA

    • Jongyoon Han
  4. BioSystems and Micromechanics (BioSyM) IRG, Singapore-MIT Alliance for Research and Technology (SMART) Centre 138602, Singapore

    • Jongyoon Han

Authors

  1. Search for Sung Hee Ko in:

  2. Search for Divya Chandra in:

  3. Search for Wei Ouyang in:

  4. Search for Taehong Kwon in:

  5. Search for Pankaj Karande in:

  6. Search for Jongyoon Han in:

Contributions

S.H.K. and J.H. conceived the project and S.H.K. designed and fabricated the device. S.H.K. conceived and performed the experiments for purity and activity monitoring with both non-degraded and degraded drugs using the at-line monitoring system and analysed the data. D.C. screened and provided peptide sequences for hGH and IFN, W.O. provided information on how to prepare the degraded drugs, T.K. cultured CHO-K1 cells in batch mode and provided IgG1. S.H.K. and J.H. wrote the manuscript, and J.H. and P.K. supervised the project.

Competing interests

J.H. and S.H.K. have filed a patent application for the nanofilter device. P.K. and D.C. plan on filing patent applications for the peptide ligands.

Corresponding author

Correspondence to Jongyoon Han.

Supplementary information

PDF files

  1. 1.

    Supplementary information

    Supplementary information

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nnano.2017.74

Further reading